Format

Send to

Choose Destination
HeartRhythm Case Rep. 2016 Mar 10;2(3):237-240. doi: 10.1016/j.hrcr.2016.01.005. eCollection 2016 May.

Flecainide and elevated liver enzymes in α1-antitrypsin deficiency.

Jenkins DJA1,2,3,4,5, Freeman M6,4, Mangat I6,5,4, Srichaikul K1,2,4,7, Jayalath VH1,2,4, Faulkner D1,2, Sievenpiper JL1,2,3,4,5, Kendall CWC1,2, Romaschin A8,5, Kim YI9,2,5,4, Dorian P4,6,5.

Author information

1
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, and Clinical Nutrition and Risk Factor Modification Center, St Michael׳s Hospital, Toronto, Ontario, Canada.
2
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
3
Division of Endocrinology and Metabolism, St Michael׳s Hospital, Toronto, Ontario, Canada.
4
Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
5
Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Ontario, Canada.
6
Division of Cardiology, Department of Cardiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
7
Department of Family and Community Medicine, St Michael's Hospital and Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
8
Department of Clinical Chemistry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
9
Division of Gastroenterology, Department of Medicine, University of Toronto and St Michael's Hospital, Toronto, Canada.

KEYWORDS:

Atrial fibrillation; Cardiovascular disease; Drug adverse event; Flecainide; Liver toxicity

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center